exRNAdisease

General Information

Database ID:

exR0088168

RNA Name:

hsa-miR-330-5p

RNA Type:

miRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

45639049

End Site(bp):

45639070

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ZNF3	chr7	100064033	100082548	-
ALDH5A1	chr6	24494867	24537207	+
ENG	chr9	127815012	127854756	-
NEMP1	chr12	57055643	57088063	-
STX3	chr11	59713456	59805882	+
RTL10	chr22	19846138	19854896	-
GIPC1	chr19	14477760	14496149	-
ANKRD13B	chr17	29589769	29614761	+
UBE4A	chr11	118359585	118399211	+
MARK2	chr11	63838928	63911019	+
ATXN1	chr6	16299112	16761491	-
NME4	chr16	396725	410367	+
TMEM127	chr2	96248516	96265994	-
PDXK	chr21	43719094	43762307	+
GUCD1	chr22	24540423	24555935	-
MTG2	chr20	62183029	62203568	+
VLDLR	chr9	2621787	2660056	+
EIF4A1	chr17	7572706	7579006	+
GIGYF1	chr7	100679507	100694037	-
DOLPP1	chr9	129081111	129090438	+
SMAD3	chr15	67063763	67195169	+
MAP4	chr3	47850690	48089272	-
ABL1	chr9	130713016	130887675	+
PAQR4	chr16	2969270	2973484	+
NR4A2	chr2	156324437	156342348	-
CRTC3	chr15	90529923	90645345	+
PPME1	chr11	74171267	74254703	+
GOSR2	chr17	46923075	46975524	+
MYO1C	chr17	1464186	1492686	-
AGTRAP	chr1	11736084	11754802	+

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000128	chr1	151139409	151139890	+
hsa_circ_0000384	chr12	27867712	27877119	+
hsa_circ_0001727	chr7	99621041	99621930	+
hsa_circ_0001865	chr9	86292641	86293514	-

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC016876.2	chr17	7581964	7584086	-
AC144548.1	chr12	110387463	110445548	-
AL355075.4	chr14	20343048	20343685	-
AL359924.1	chr1	237862175	237928321	+
AP000553.1	chr22	21652270	21670237	+
KCNQ1OT1	chr11	2608328	2699994	-
MIRLET7BHG	chr22	46053869	46113928	+
NEAT1	chr11	65422774	65445540	+
SNHG1	chr11	62851984	62855953	-
SNHG3	chr1	28505980	28510892	+
TUG1	chr22	30969245	30979395	+
XIST	chrX	73820649	73852723	-

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.